The disclosure relates to combination therapies using anti CD38 antibodies. Specifically the disclosure provides methods of treating a subject having acute lymphoblastic leukemia (ALL) using an anti CD38 antibody wherein the anti CD38 antibody induces in vitro killing of ALL cells by antibody dependent cell mediated cytotoxicity (ADCC) antibody dependent cellular phagocytosis (ADCP) complement dependent cytotoxicity (CDC) apoptosis or in vitro modulation of CD38 enzymatic activity.